Chronic Prostatitis

Product Candidate Description

The molecule used for this therapy is an FDA-approved product which, in Beech Tree’s hands, is formulated as an oral drop at a concentration several thousand times lower than usually used by injection for other indications.

Laboratory Status

Some mechanism-of-action studies have been completed and the data licensed to Beech Tree from Milkhaus Laboratory. Further work needs to be completed using lab animal models to study the effect of this agent at the sub-molecular level.

Clinical Status

A small, double-blind study was conducted at Stanford University Medical School with positive results and placebo-level adverse reactions. That IND is still open, has been assigned to BTL, and could be rapidly re-started.

Path Forward

Expanding the earlier FDA-authorized trial is a priority. With a disease increasing in incidence as the population ages, and in a market where there are no prescription products for this indication, this would appear to be a prime candidate for early development.